Search results
Showing 7381 to 7395 of 7728 results
This guideline has been updated and replaced by the NICE guideline on head injury: assessment and management (NG232).
Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]
Discontinued [GID-TA10869]
In development [GID-TA11273] Expected publication date: TBC
In development [GID-TA10726] Expected publication date: TBC
November 2024: This evidence summary has been withdrawn because licensed products are now available.
This guidance has been updated and replaced by NICE interventional procedures guidance 737.
October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.
This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).
This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).
This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).
This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
In development [GID-TA11086] Expected publication date: TBC
In development [GID-TA11441] Expected publication date: TBC
Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]
Discontinued [GID-TA11261]